Cargando…

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

BACKGROUND: Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis, suppressing glucagon secretion, and delaying gastric em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shyangdan, Deepson S, Royle, Pamela L, Clar, Christine, Sharma, Pawana, Waugh, Norman R
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3017518/ https://www.ncbi.nlm.nih.gov/pubmed/21143938 http://dx.doi.org/10.1186/1472-6823-10-20

Ejemplares similares

Current treatments in diabetic macular oedema: systematic review and meta-analysis
por: Ford, John Alexander, et al.
Publicado: (2013)

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide
por: Gurung, Tara, et al.
Publicado: (2015)

SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2016)

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review
por: Ford, John A, et al.
Publicado: (2012)

Adding Pioglitazone to Insulin Containing Regimens in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Clar, Christine, et al.
Publicado: (2009)

Treatments for macular oedema following central retinal vein occlusion: systematic review
por: Ford, John A, et al.
Publicado: (2014)

Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis
por: Ford, John A, et al.
Publicado: (2014)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
por: Riederer, A., et al.
Publicado: (2016)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus
por: Patel, Vishal J, et al.
Publicado: (2018)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
por: Mehan, Sidharth, et al.
Publicado: (2022)

Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus
por: Onoviran, Olusola F., et al.
Publicado: (2019)

Correlation between gut microbiota and glucagon-like peptide-1 in patients with gestational diabetes mellitus
por: Liang, Yun-Yi, et al.
Publicado: (2022)

Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats
por: Chen, Yen-Cheng, et al.
Publicado: (2017)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
por: Kjaer, Marie, et al.
Publicado: (2020)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Effect of glucagon‐like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
por: Yuan, Daniel, et al.
Publicado: (2022)

Systematic reviews of epidemiology in diabetes: finding the evidence
por: Royle, Pamela, et al.
Publicado: (2005)

Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine
por: Tang, Hsin-Chieh, et al.
Publicado: (2014)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Cho, Young Min, et al.
Publicado: (2013)

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
por: Deane, Adam M, et al.
Publicado: (2010)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis
por: Jiang, Yawen, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Cognitive Decline and Dementia in Diabetes Mellitus
por: Pelle, Maria Chiara, et al.
Publicado: (2023)

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
por: Clar, Christine, et al.
Publicado: (2012)

The Possible Protective Role of Glucagon-Like Peptide 1 on Endothelium During the Meal and Evidence for an “Endothelial Resistance” to Glucagon-Like Peptide 1 in Diabetes
por: Ceriello, Antonio, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oshmf0m1pb3u81saph6cihmogv